Mid
J
JNJAI Stock Diagnostic Report
J&J long-term Tremfya data demonstrates Crohn's remission through three years
J&J's Tremfya is positive on long-term data showing a clinical remission rate of up to 94% over three years in Crohn's disease patients.
View Source Article ↗AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICE$263.73Reference entry price at analysis time
01
FUNDAMENTALS
Financial & Fundamental Analysis
Tremfya's long-term clinical success is expected to contribute to mid- and long-term sales stability by solidifying its market dominance in key autoimmune disease treatments.
02
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Through the GALAXI 2 and GALAXI 3 Phase 3 clinical trials, the clinical value of the pipeline was demonstrated by recording a clinical remission rate for Crohn's disease of up to 94% over three years.